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Abstract
Shared decision making (SDM) - involving patients in decisions relevant to their health - has been increasingly
influential in medical thought and practice around the world. This paper reviews the current status of SDM in
Israel, including efforts to promote SDM in the legislation and healthcare system, its influence in medical training
and the national health plans, and funding for SDM-related research. Published studies of SDM in Israel are also
reviewed. Although informed consent and patients’ right to information are regulated by Israeli law, little provision
is made for SDM. Further, there are few organized programs to promote SDM among medical professionals or the
public, and governmental support of SDM-related research is minimal. Nonetheless, patients have begun to
influence litigation in both formal and informal capacities, medical schools have begun to incorporate courses for
improving physician-patient communication into their curricula, and the largest national health plan has initiated a
plan to increase public awareness. A review of the limited research literature suggests that although patients and
physicians express a desire for greater patient involvement, they often have reservations about its implementation.
Research also suggests that despite the positive effects of SDM, such an approach may only infrequently be
applied in actual clinical practice. In conclusion, though not actively promoting SDM at present, Israel’s universal
coverage and small number of health plans make rapid, widespread advances in SDM feasible. Israeli policymakers
should thus be encouraged to nurture burgeoning initiatives and set plausible milestones. Comparing the status of
SDM in Israel with that in other countries may stimulate further advancement.
Keywords: Shared decision-making, Israel, patient autonomy, informed consent, health care system, patient
participation
1. The importance of shared decision making
(SDM) in healthcare
Shared decision making (SDM), “the attempt to involve
patients in decision-making tasks, especially where deci-
sions, in the face of uncertain or equivocal evidence of
benefit, are sensitive to personal preferences” [1], has
grown in prevalence worldwide over the last two dec-
ades [2]. SDM relates to involving patients in various
issues, including screening, treatment options, adminis-
tration of medication, nutrition, and lifestyle interven-
tions. SDM has influenced the way medicine is practiced
and has sparked interest in exploring ways to involve
patients in their healthcare decisions and measure the
effects of this involvement [3].
Indeed most patients wish to take an active part in
choosing among alternative courses of action regarding
their health, with the physician either participating in
the decision or providing relevant information and then
allowing the patient to decide autonomously [4]. Beyond
the higher ethical standards associated with greater
patient involvement as compared with physician patern-
alism, SDM has practical merits. An impressive corpus
of research has shown that patient involvement leads to
better knowledge about treatment options, more realistic
expectations concerning disease course and treatment,
improved adherence, enhanced patient satisfaction, and
sometimes a better clinical outcome [5].
Though ultimately manifest at the level of the patient-
physician encounter, SDM must first be legally man-
dated and medical professionals must be trained to
incorporate its principles into their practice. Further,
research studies are necessary to monitor its status and
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drive improvement. Moreover, these activities must be
supported and promoted by national health, legal, and
other organizations. Some countries have allocated
resources for the promotion and evaluation of SDM. In
Germany, the ministry of health funded the research
consortium ‘’Patient as partner in medical decision-mak-
ing’’ [6]. In Canada, the importance of SDM is reflected
in increased funding for medical training and initiatives
to incorporate patient decision aids in medical care [7].
In view of the growing global prevalence and interest in
SDM, periodic country-specific status reports facilitate
comparison both between and within countries over
time. The purpose of the present review is to outline
the status of SDM in Israel, a country where universal
healthcare coverage and a small number of national
health plans make sweeping advances in SDM feasible.
Indeed we hope to generate fresh interest in furthering
this important approach in Israel.
Portions of this paper (reproduced with permission)
have previously been published in abridged form in a
special issue of the German Journal for Evidence and
Quality in Healthcare (ZEFQ) on the global status of
SDM [8]. Unlike the ZEFQ paper, the present paper
makes specific recommendations and provides a more
extensive treatment of the relevant topics, as well as the
above background on SDM. Further, as the present
paper was written for an Israeli audience, there was no
need to include background on Israeli demographics,
health care spending, and the health care system
included in the ZEFQ paper.
2. Efforts to promote SDM in the Israeli
legislation and healthcare system
2.1 The micro level: Patient involvement in their own care
Though there is no direct, explicit mandate for SDM in
Israeli law, as will be explained below, the requisite con-
ditions are encapsulated in the Patients’ Rights Law of
1996. Prior to its passage, support for SDM in Israeli
legislation was limited to a clause in the national health
insurance law requiring each health plan to furnish a
description of its services and make them available to
members upon request.
Patients’ Rights Law
The Patients’ Rights Law (hereinafter “the Law”) was
enacted in 1996 after five private initiatives were com-
bined to form one national proposal. The Law empha-
sized that patients have rights above and beyond the
right to health care alone and was the product of coop-
eration between members of the Israeli Parliament, gov-
ernment offices, the Association for Civil Rights in Israel,
religious and legal representatives, women’s organizations
and patient and professional associations. The Law
defined the rights and obligations of patient-provider
relationships, reflecting the shift from a paternalistic
model of care to a patient-centered model emphasizing
patient autonomy. The main goals of the Law were to
define the rights of the patient and protect the patient’s
dignity and privacy. The Law included rights that were
previously recognized in medical ethics and by social and
legal norms (e.g., prohibition against discrimination,
informed consent, patient access to medical records,
privacy of medical information).
The Law relates to medical decision making as an act
performed by the physician that may not be executed
without the patient’s consent. Thus, the Law is mainly
concerned with the clinician’s duty of disclosure, as
required for the patient’s informed consent to medical
treatment. Yet, these requirements set the necessary
conditions for a process of SDM. According to the Law,
informed consent must be based on data about the diag-
nosis and prognosis, the nature of the proposed treat-
ment, expected benefits and likelihood of success, the
risks and side effects involved (including pain and dis-
comfort) and those of alternative treatments (whether
covered by national health insurance or not) or the lack
of any treatment at all. These requirements are the hall-
marks of a good decision process characterized by SDM
[9]. The clinician is required to “supply the patient med-
ical information to a reasonable extent, so as to enable
the patient to decide whether to agree to the treatment
proposed” [10]. Thus disclosure according to the Law,
must satisfy both what most people in the patient’s posi-
tion would want to know (similar rulings exist in the
US, Canada, Australia, and the UK [11-14]) and the
needs of the individual patient (similar rulings exist in
Germany, Switzerland, and Austria [15]). Several inter-
pretations of the Law suggest that this dual standard for
disclosure requires a dialogue with the patient to
explore her/his information needs and the extent to
which s/he is interested in details about the proposed
treatment and its alternatives [16,17].
The Law further states that the clinician shall provide
the information to the patient at the earliest stage of the
treatment in a manner that maximizes the ability of the
patient to understand the information and make a free
and independent choice. The consent may be given verb-
ally, in writing, or demonstrated by the patient’s behavior.
For certain treatments,a informed consent must be given
in writing [10]. Notably, the patient’s right to refuse treat-
ment is not absolute under the Law. If a patient is in grave
danger, the clinician may refer the case to an Ethics Com-
mittee for consideration of treatment against the patient’s
will. In these exceptional situations, the Committee is
obliged to listen to the patient and consider whether in
the given circumstances, there are reasonable grounds to
assume that, after receiving treatment, the patient will give
his retroactive consent. The patient’s right to access to
medical information is similarly limited by clinical
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privilege (i.e., the clinician may withhold medical informa-
tion from the patient concerning his medical condition if
doing so may be harmful or life-threatening to the
patient), again following Ethics Committee approval.
Following enactment of the Law, informed consent
became a central issue in malpractice litigation, particu-
larly with regard to adequate communication of the
risks associated with a particular treatment, its likeli-
hood of success, and/or the availability of alternative
treatments [16]. In 1999 the Israeli Supreme Court
handed down a landmark ruling that interference with a
patient’s right to autonomy is a recognized damage [18].
Thus a patient may be granted dignitary damages for
failure to disclose information relevant to the treatment
decision even when injury causation or decision causa-
tion cannot be proven.
The Dying Patient Act
The Dying Patient Act of 2005 (hereinafter “the Act”) is
consistent with SDM in stipulating that decisions con-
cerning dying patients consider the patient’s wishes in
addition to the medical condition and degree of suffer-
ing. The Act requires that the patient’s wishes be peri-
odically reassessed. If the patient is competent at the
time of the decision, the determination would be made
in accord with the patient’s wishes. If the patient is not
competent, the physician is instructed to rely upon the
patient’s previously expressed wishes, either directly or
from testimonies of close family and friends.
Autonomous patient requests for active euthanasia or
physician-assisted suicide would not be honored under
the Act as they are prohibited based upon religious con-
siderations enacted into Israeli law [19]. However, the
Israeli Parliament is soon to consider a November 2010
bill that would allow the prescription of lethal drugs to
a dying patient upon the patient’s request [20]. The bill,
modeled upon the Oregon Death with Dignity Act [21],
proposes that competent patients be permitted to
request the prescription of a lethal drug, provided they
are diagnosed with a terminal illness expected to result
in death within six months. Still, in keeping with the
Act, lethal medication should not be provided immedi-
ately upon request, but only after a concerted effort to
assess and ameliorate the patient’s physical and mental
condition [22].
Recent initiatives
Israel’s population is a heterogeneous mix of immigrants
affiliated with three major religions (Judaism, Christian-
ity, Islam) from many different countries, including
Ukraine, Ethiopia, Morocco, and the United States. Con-
sequently, there is a diversity of patient beliefs about the
degree to which the doctor is the absolute medical
authority. Moreover, securing informed consent and
access to medical information and services to all Israeli
citizens is a significant challenge [23]. The Ministry of
Health has pledged to address cultural and language
issues associated with provision of services in its 2011-
2014 policy plan [24]. Specifically, the Ministry seeks to
provide (a) guidance to health services providers regard-
ing the required standard for language and cultural
accessibility, (b) training to caregivers in cultural appro-
priateness, and (c) culturally appropriate materials on
health topics, benefits, informed consent, etc. in a vari-
ety of languages.
2.2 The macro level: Patient involvement in health policy
Public involvement in Israeli health policy has included
a variety of formal and informal activities, programs and
discussions [25].
Formal involvement
Israeli citizens serve on the boards of national health
plans and as members of the National Health Council, a
nationally representative advisory body to the Ministry of
Health [23]. Additionally the Ministry of Health has
formed ad hoc committees that include citizen and pro-
fessional representation. Committees have dealt with
such sensitive policy issues as care of terminally ill and
dying patients, fertility and procreation, and implementa-
tion of a national electronic medical records system
[23,26]. Notably, formal bodies seldom include ordinary
citizens [23]. For example, only 6 of the 46 members of
the National Health Council are non-health profes-
sionals, and of these, only two are members suggested by
patient advocacy organizations [27].
One prominent committee is the public committee to
revise the set of health services benefits to which every
Israeli citizen is legally entitled (known in Israel as ‘the
health basket’). As of this writing, the committee’s
recommendations regarding technologies to be added to
the ‘basket’, though not legally binding, have been fully
adopted. The ‘basket’ committee is comprised of repre-
sentatives from the government, the national health
plans, and the public. A 2007 government ruling calls for
a 16 member committee, four of whom come from the
public sector, including experts in ethics [28]. In general,
25% of ‘basket’ committee members have been ordinary
citizens with no medical background [29,30].
In 2003 Israel inaugurated the “Health Parliament” to
involve citizens from diverse segments of the population
in a deliberative process regarding allocation of public
funds for healthcare services. Approximately 130 indivi-
duals, randomly selected from all over the country,
received extensive orientation to pressing health policy
issues from leading experts, and then met to discuss
dilemmas associated with equality in health services and
prioritization of technologies for funding [31]. Summaries
of the proceedings and recommendations of the Health
Parliament were presented to the Minister of Health and
senior healthcare decision-makers. The initiative was
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discontinued the following year due to funding problems
[32].
Informal involvement
There are approximately fifty patient advocacy groups in
Israel today, some linked to specific diseases. Members
appear at public legal proceedings and are involved in
lobbying against government policies that conflict with
patient interests. Groups may function individually or in
concert with one another, as coordinated by the Israeli
Health Consumers’ Organization (Z.V.I.) [25] or by a
coalition formed by the The Society for Patients’ Rights
in 2008.
3. SDM in Israeli medical training and the
national health plans
The deans of all four Israeli medical schools indicated
that there were no organized programs to promote
SDM at their medical schools or affiliated hospitals.
However, courses for improving patient-physician com-
munication have been developed and included in the
curricula of most medical schools. At Tel Aviv Univer-
sity, patient empowerment is taught both in formal
courses on professionalism and ethics and in simulated
role-playing; it is also incorporated into a new ‘physician
charter’ adopted by the Faculty of Medicine. At the
Hebrew University, the genetic counseling program
offers a course on the psychological aspects of decision-
making (developed and taught by the first author) in
which future counselors learn about the difficulties in
understanding and processing risk information by
adopting the perspective of a counselee [33]. The Israel
Center for Medical Simulation (MSR), a national, multi-
modality, interdisciplinary simulation center based at
Sheba Medical Center, offers a wide range of courses
designed to improve patient-physician communication
skills by exposing students to simulated clinical encoun-
ters [34,35].
Key personnel affiliated with the four national health
plans in Israel indicated that there were no organized
programs to promote SDM among their healthcare pro-
viders. However, following a successful pilot [36], the lar-
gest health plan (’Clalit’) inaugurated a national “Ask Me
3” program to create awareness and reinforce clear health
communication, as well as emphasize the patient’s role in
the medical encounter [37]. The program focuses on
three questions: “What is my main problem?”, “What do
I need to do?”, and “Why is it important for me to do
this?” A recent study designed to set a baseline for later
evaluation of “Ask Me 3” at a major medical center in
southern Israel, revealed that 67% of female patients
reported asking questions of the medical staff during
their hospitalization, but only 33% of patients reported
that the staff encouraged such questions [38].
4. Research agenda on SDM
In June 1995 the National Health Council designated
the Israel National Institute for Health Policy and
Health Services Research (NIHP) to oversee implemen-
tation of the national health insurance system, conduct
relevant research, including surveys, and procure expert
professional opinion [39]. The number of SDM-related
research studies funded by the NIHP can be taken to
reflect the relative importance of SDM to the Israeli
research community. Of the 396 NIHP-funded research
studies between 1998 and 2010, only 3% were related to
SDM. Among these were studies on such topics as
engaging psychiatric patients in illness management and
the effect of patient participation in improving diabetes
management in primary care.
Though the number of studies on a particular topic
funded by the NIHP is highly influenced by the number
of proposals submitted on that topic and their quality, we
believe NIHP should have a clear agenda for evaluating
and promoting SDM in Israel, and allocate funds ear-
marked for this purpose. As a first step, we suggest that
the NIHP fund a national project to characterize the sta-
tus of SDM in Israel, including population data on the
prevalence of SDM in clinical practice, subdivided by
medical setting. Such a project would also summarize
correlates of SDM (e.g., clinical outcomes), as well as bar-
riers to its adoption (see section 6.). Subsequent projects
should develop targeted approaches for promoting SDM
and assess their efficacy relative to the prior baseline.
One such related topic, which could serve as a demon-
stration project, is prenatal screening, where women are
often not fully informed of the meaning of specific
screening procedures [40]. We propose that introducing
shared decision making to this area might serve to
demonstrate the shift incurred in health practices (e.g.,
avoiding the triple serum screening when one has already
decided to undergo amniocentesis), as well as in costs,
when patients are invited and equipped to participate in
the decision making process.
5. Studies of SDM in Israel
In this section, we summarize studies that have investi-
gated SDM in Israel. These studies provide important
insights into the factors surrounding sensibilities and
issues related to SDM in Israel and thus serve as a context
for the development of suitable and effective interventions.
We conducted a literature search for relevant articles
using Web of Science SCI-EXPANDED, SSCI, and
A&HCI databases, EMBASE, PubMed and Google Scho-
lar, with the search terms ‘informed consent’, ‘patient par-
ticipation’ and ‘shared decision making’, all in conjunction
with ‘Israel’. We aimed to include papers published after
2000. Additionally, to facilitate a comprehensive and
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current review, we queried members of the Israeli Social
Sciences network, asking them to direct us to relevant
works in print or in progress. Though not an exhaustive
review of SDM works pertaining to Israel, we believe the
following gives a good indication of the type of research
being performed, as well as the major trends characteriz-
ing the Israeli zeitgeist on SDM.
Physician advocacy of SDM
Israeli PCPs (N = 141) were presented with a vignette
describing a hypothetical clinical encounter involving a
calm and cooperative or agitated and uncooperative Alz-
heimer’s disease patient and her caregiver [41]. PCPs
indicated that they would question, inform, and involve
the caregiver (i.e., family), more consistently than the
patient, particularly when the patient was agitated. Most
PCPs (89%) stated they would reach a decision with the
family, 6% stated they would decide paternalistically,
and less than 5% stated they would let the family decide
autonomously.
SDM is greatly facilitated by the accessibility of medi-
cal information on the internet, given that it is directly
available to patients. Most Israeli PCPs (82%, N = 118; a
representative sample) agreed that patient internet use
indicates patient involvement and accountability for
their medical care. Similarly, 59% expressed satisfaction
over patients bringing materials from the internet to the
consultation. Regardless, 34% of PCPs felt that the
patient or family should rely solely on the physician
[42].
Patient advocacy of SDM
Israeli, locally representative hospitalized and ambulatory
patients (N = 274) ranked six issues in terms of priority
for improvement [43]. Obtaining more information from
the physician and participating in decisionsb was ranked
most desirable, with 27% ranking it as their top priority
and 13% as their second priority. Easier access to specia-
lists or hospital services was ranked next highest, with
18% of patients ranking this top priority and 20% second
priority.
Similarly, 613 Israeli hospitalized patients undergoing
invasive procedures in various clinical settings were asked
about the quality of their informed consent [44]. Though
98% of patients recalled having signed an informed con-
sent, only 39 to 60% recalled receiving explanations about
risks of procedures, and 8 to 40% remembered a discus-
sion about alternative management options. Regardless,
80% of patients rated overall satisfaction with the decision
making as good or very good, and satisfaction did not
correlate with recall of information.
Additionally, 496 of the hospitalized patients and 350
Israeli ambulatory patients indicated their preference for
an autonomous, paternalistic, or shared decision-making
process [44]. In both settings, approximately 60% of
patients preferred SDM, 20% autonomous decision-mak-
ing, and the remainder paternalistic decision-making.c
SDM involves not only physician and patient, but also
close family members who may be significantly affected by
the consequences of medical decisionsd. Almost all breast
cancer patients interviewed 3-12 months after diagnosis
(93%) felt it was important for them to autonomously
make medical decisions, but a similar number felt physi-
cian (95%) and spousal (89%) concurrence with the treat-
ment decision was important. Interestingly, most patients
(88%) and spouses (82%) preferred the physician to make
the final decision, possibly reflecting an aversion to the
burden borne by the decision-maker, even at the cost of
reduced autonomy [45].
In a study investigating perceptions of patient partici-
pation in the four national health plans [46], patients
(N = 656, a nationally representative random sample)
did not feel that they were part of the decision-making
process in their health plans. Moreover, perception of
patient participation was positively correlated with per-
ception of health plan performance.
SDM in end-of-life care
In a survey on the use of life-sustaining treatments in
terminal illness, physician (N = 339) and patient (a ran-
dom sample of 987 elderly Israelis) views were incongru-
ous [47]. Specifically, physicians would order significantly
more life-sustaining treatments than patients would want
or would order for themselves in the same position.
These incongruities may be attributable to cultural
norms underlying Israeli medical practice and may be
ameliorated by promoting open communication between
physicians and patients.
SDM in actual clinical practice
A qualitative study evaluated whether strategies used by 17
pediatric gastroenterologists to inform adolescents and
their families of a diagnosis of irritable bowel syndrome
(IBS) and discuss treatment options could be characterized
as shared or paternalistic [48]. When interviewed, physi-
cians independently included SDM principles in describing
their routine practice. However, observation of the clinical
encounters revealed that physicians used tactics to per-
suade patients to agree with their preferred treatment
choice that ultimately reduced patient-physician trust and
resulted in low compliance.
Additional evidence for the lack of SDM in actual clini-
cal practice comes from an analysis of 291 videotaped
encounters with Israeli PCPs and found that 21% of con-
flicts related to rationing of health care resources [49].
PCPs most commonly dealt with resource rationing by
accepting the situation and withholding alternative treat-
ment options within (appealing rules) or outside of the
national health insurance system from their patients.
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Initiatives to promote SDM
PANDEX is a web-based application incorporating deci-
sion-analytic methods to assist patients and care provi-
ders to reach optimal deliberative decisions [50]. In a
pre-clinical feasibility study, Israeli genetic consultants
were presented with scenarios of women who had come
for genetic consultation, and with PANDEX recommen-
dations for each scenario. Consultants tended to agree
with the strategies recommended by PANDEX and
acknowledged its capability to provide important insight
and serve as a useful tool for patients prior to their
meeting with the genetic consultant. Nevertheless, con-
sultants expressed reservations about the integration of
a PANDEX-like decision support system in medical
care, apparently reflecting their view that consultants
play an essential role in both explaining genetic infor-
mation and facilitating the decision making process.
Recent applications of PANDEX in the prenatal con-
text find that though PANDEX recommended no more
than two tests per patient, most patients actually under-
went nearly all six of the available tests, and that the
PANDEX recommendation was highly influenced by test
order [40]. Thus, PANDEX should not serve as the deci-
sion-maker, but rather its recommendations should sti-
mulate patient-physician dialogue.
6. Barriers to Adoption of SDM
In this section we describe potential barriers to wide-
spread adoption of SDM in Israel. One such barrier is
patient and physician ambivalence. As above, although
patients indicate a desire for increased involvement, they
appear happy with their care and defer difficult deci-
sions to the physician. Similarly, physicians express sup-
port for SDM, but often withhold information from
patients or apply persuasion tactics so that patients
choose the physician’s preferred course of action. We
believe that this ambivalence, whereby patients and phy-
sicians agree with SDM in principle, but are reluctant to
incorporate it in practice, represents a significant barrier
to the adoption of SDM.
Physician ambivalence may be rooted in another
important barrier: lack of formal coursework on SDM in
medical education. As a consequence, physicians are
untrained in engaging in SDM (even if they desire to do
so) and may adopt views inconsistent with SDM. For
example, current medical education emphasizes a need
for certainty that later compromises the physician’s abil-
ity to communicate the relative merits of treatment
options to patients [51-53]. Also, physicians may avoid
disclosure based upon a perception of informed consent
as a legal burden. Finally, physicians may interpret the
lack of formal coursework as an indication that the
medical establishment does not advocate SDM in medi-
cal practice.
Another potential barrier pertains to ‘collective statis-
tical illiteracy’ among physicians and patients [51].
Indeed many physicians are not proficient in interpret-
ing risk and benefit information and will consequently
be ill-equipped to explain such information to patients.
Patients, as well, are typically not proficient in interpret-
ing such statistics, exacerbating their natural tendency
toward reticence in the clinical encounter [54]. Thus
rather than discuss information they do not understand,
physicians and patients may tend to avoid the type of
risk/benefit discourse that characterizes SDM. Moreover,
lack of statistical comprehension may lead to a construal
of the patient’s role as passive rather than informed and
participatory [32].
Critically, as indicated above, a nationally-funded
population-based study is necessary to firmly evaluate
the presence or absence of these barriers in actual clini-
cal practice. Follow-up studies may then systematically
evaluate the efficacy of interventions to overcome them.
This data can then be used to encourage medical
schools and health plans to implement these interven-
tions through such channels as the National Health
Council and informal patient advocacy groups.
7. Conclusions and policy implications
Indeed, burgeoning initiatives to promote SDM in medi-
cal training and practice reflect a growing interest in
patient involvement. Only by nurturing these initiatives
and with continued support for SDM at multiple levels
can efforts to promote SDM be advanced, ultimately
resulting in a greater role for citizens in their healthcare
and health outcomes. Such advances may serve as a
model for furthering SDM in other countries, particu-
larly those with similar national healthcare systems.
This review indicates that Israel possesses the requisite
legislative and research infrastructure to facilitate
informed patients who are active participants in deci-
sions pertaining to their health: Israel’s universal cover-
age and small number of health plans make rapid,
widespread advances in SDM feasible. It is our hope
that this review will empower and encourage patient
advocacy groups and ultimately policymakers in Israel
to advance SDM, aiding them in devising a viable plan
with plausibly attainable milestones. Policymakers
should focus on funding a population-based project to
characterize the status of SDM in Israel, in tandem with
engaging and mobilizing medical schools, the national
health plans, and practitioners to facilitate the process.
Annual audits of the Ministry of Health may be used to
track progress.
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Endnotes
aSurgery, other than minor surgery; blood vessel catheterization; dialysis;
radiotherapy; in-vitro fertilization; chemotherapy for malignancies. bAs
participants rated additional information and greater involvement in
decision-making as a single item [43], patient preferences for improvement
in each of these aspects separately cannot be determined. cThese findings
are in agreement with those of a study in European patients, of whom 51%
favored SDM, 23% autonomous, and the remainder paternalistic decision-
making [4]. dThough Israeli law (as in the UK) requires only that the
physician involve the patient; no provision is made for close family [55].
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